Evidence map›Paper›PMID 38441775›Full record

ReviewInternational journal of hematology2024

Characteristics and literature review of ETV6::ABL1 fusion gene-positive acute myeloid leukemia.

Song Xue, Hui-Peng Sun, Xiao-Bing Huang, Xue Chen, Tong Wang, Wei Ma, Yao Tian, Zhi-Lan Pan, Li-Hong Li, Lu Zhang and 2 more

Abstract readReviewCase Reports
PubMed Publisher
In one paragraph

Review in International journal of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 1 country.

Song Xue *Department of Bone Marrow Transplant, Beijing Lu Daopei Hospital, Beijing, 100176, China.
Hui-Peng Sun *Division of Pathology and Laboratory Medicine, Beijing Lu Daopei Hospital, Beijing, 100176, China.
Xiao-Bing Huang *Department of Hematology, Sichuan Provincial People's Hospital, Affiliated Hospital of University of Electronic Science and Technology of China, Chengdu, 610072, China.
Xue ChenDepartment of Laboratory Medicine, Hebei Yanda Lu Daopei Hospital, Langfang, 065201, China.
Tong WangDepartment of Laboratory Medicine, Hebei Yanda Lu Daopei Hospital, Langfang, 065201, China.
Wei MaDepartment of Bone Marrow Transplant, Hebei Yanda Lu Daopei Hospital, Yanjiao Economic and Technological Development Zone, Si Pu Lan Road, Langfang, 065201, Hebei, People's Republic of China.
Yao TianDepartment of Hematology, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150001, China.
Zhi-Lan PanDepartment of Hematology, Shijiazhuang People's Hospital, Shijiazhuang, 050000, China.
Li-Hong LiDepartment of Hematology, Shijiazhuang People's Hospital, Shijiazhuang, 050000, China.
Lu ZhangDepartment of Hematology, Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, PekingBeijing, China.
Hong-Xing LiuDepartment of Laboratory Medicine, Hebei Yanda Lu Daopei Hospital, Langfang, 065201, China.
Xing-Yu CaoDepartment of Bone Marrow Transplant, Hebei Yanda Lu Daopei Hospital, Yanjiao Economic and Technological Development Zone, Si Pu Lan Road, Langfang, 065201, Hebei, People's Republic of China. caoxingyu2020@sina.com.
Luye Pharma (China) · CNBeijing Dao Pei Hospital · CNFirst Hospital of Shijiazhuang · CNHospital of Hebei Province · CNPeking Union Medical College Hospital · CNSecond Affiliated Hospital of Harbin Medical University · CNUniversity of Electronic Science and Technology of China · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo describe the features of ETV6::ABL1 AML as well as the clinical treatment and outcomes.

methodsClinical data were collected from three patients diagnosed with ETV6::ABL1 AML at Hebei Yanda Lu Daopei Hospital and Beijing Lu Daopei Hospital. Their clinical and laboratory features were analyzed, and the treatment process and outcomes were described. Ten reported cases of ETV6::ABL1 AML from the literature were also included for analysis.

resultsThe median age of the patients was 34 years, and 2 patients were male. No patient had a history of blood disorders before diagnosis. After relapse, they were referred to our hospital, where the ETV6::ABL1 gene was detected. Unfortunately, Patient 1 died rapidly after leukemia relapse due to severe infection. Patients 2 and 3 received salvage therapy with a dasatinib-containing regimen, followed by allo-HSCT, and are currently alive and disease-free.

conclusionETV6::ABL1 is a rare but recurrent genetic aberration in AML, and the combined use of fluorescence in situ hybridization and PCR can better identify this fusion gene. Patients carrying ETV6::ABL1 have a high relapse rate and a poor prognosis. TKIs are a reasonable treatment option for this group, and allo-HSCT may be curative.

Indexed as

ETS Translocation Variant 6 ProteinLeukemia, Myeloid, AcuteOncogene Proteins, FusionProto-Oncogene Proteins c-etsRepressor ProteinsAdultFemaleHematopoietic Stem Cell TransplantationHumansMaleMiddle AgedProto-Oncogene Proteins c-ablTreatment OutcomeABL1 protein, humanETS Translocation Variant 6 ProteinETV6 protein, humanOncogene Proteins, FusionProto-Oncogene Proteins c-ablProto-Oncogene Proteins c-etsRepressor ProteinsAcute myeloid leukemiaAllogeneic hematopoietic stem cell transplantationETV6::ABL1Tyrosine kinase inhibitors

Identifiers

PMID38441775
OpenAlexW4392473579

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.